Showing results (151-160 of 302) with videos related to

Sort By:
Pageof 31
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisCindy Franklin, Isabelle Rooms, Melanie Fiedler, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 1, 2026
Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centersNina Flatt, Corinna Kochanek, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2019
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaTheodora Kanaki, Andreas Stang, Ralf Gutzmer, et al.
ESC Heart Failure|July 27, 2022
Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapyJulia Pohl, Matthias Totzeck, Raluca-I Mincu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 14, 2013
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasKlaus G Griewank, Bastian Schilling, Rajmohan Murali, et al.
Cardio-Oncology (London, England)|June 17, 2026
Cardiac dysfunction during immune checkpoint inhibitor therapy: association with extracardiac immune-related adverse eventsRaluca I Mincu, Lena Lampe, Lars Michel, et al.
British Journal of Cancer|April 9, 2026
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarkerElena Sophia Lindner, Jakob Admard, German Demidov, et al.
Pageof 31